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ORIGINAL ARTICLE
Randomised controlled trial of colostrum to improve intestinal
function in patients with short bowel syndrome
P Lund1,2, PT Sangild2, L Aunsholt3, B Hartmann4, JJ Holst4, J Mortensen5, PB Mortensen1 and PB Jeppesen1
BACKGROUND/OBJECTIVES: Colostrum is rich in immunoregulatory, antimicrobial and trophic components supporting intestinal
development and function in newborns. We assessed whether bovine colostrum could enhance intestinal adaptation and function
in adult short bowel syndrome (SBS) patients.
SUBJECTS/METHODS: Twelve SBS patients in this randomised cross-over study received 4 weeks oral supplement of bovine
colostrum or an iso-energetic and iso-proteinaceous control (2.4MJ/d, 500ml/day) separated by a 4-week washout period. Patients
were admitted four times for 72-h periods of ﬂuid, electrolyte and nutrient balance studies. Meals, faeces and urine were weighed,
and energy, macronutrient and electrolyte contents were analysed to calculate net nutrient uptake. Body composition was
measured by dual-energy X-ray absorptiometry scans, and functional tests of handgrip strength and lung functions were
performed. Eight patients completed the study and were included in the analysis.
RESULTS: Both supplements (colostrum and control) not only increased protein (0.96±0.42MJ/d, P¼ 0.004 1.03±0.44MJ/d,
P¼ 0.003) and energy (1.46±1.02MJ/d, P¼ 0.005, 1.76±1.46MJ/d, P¼ 0.01) absorption but also absolute faecal wet weight
excretions (231±248 g/d, P¼ 0.002, 319±299 g/d, P¼ 0.03), compared with baseline measurements. Both supplements improved
handgrip strength (P¼ 0.03) while only the control supplement increased lean body mass (1.12±1.33 kg, Po0.049). Colostrum
was not found to be superior to the control.
CONCLUSION: Intake of high-protein milk supplements increased net nutrient absorption for adult SBS patients, but at the expense
of increased diarrhoea. Despite high contents of bioactive factors, colostrum did not signiﬁcantly improve intestinal absorption,
body composition or functional tests compared with the control.
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INTRODUCTION
Short bowel syndrome (SBS) results from surgical resection,
congenital defect or disease-associated loss of intestinal absorp-
tion. Short bowel patients are characterised by an inability to
maintain ﬂuid, electrolyte, trace element, vitamin or nutrient
balances when fed a conventional diet.1 A borderline separates
the SBS patients with intestinal insufﬁciency, who manage without
parenteral support, from the SBS intestinal failure patients, who
depend on parental ﬂuids, electrolytes, trace elements, vitamins
and/or nutrients to maintain equilibrium, body composition,
function and health.2 Clinical treatment of SBS patients aims to
improve health by maximising intestinal absorption and reducing
the extent of diarrhoea and need for parenteral support.3,4 A key
goal is to promote maximal intestinal adaptation, the process
of recovery of intestinal function after injury or resection.5 SBS
patients are generally encouraged to compensate for mala-
bsorption by implementing a degree of hyperphagia.6,7
Treatment strategies have included changes in diet composi-
tion, for example, high-carbohydrate and low fat-diets8 or
addition of single nutrients such as glutamine,9 medium
chain triglycerides10 or bile acids.11 Continuous enteral hyper-
alimentation has been suggested to improve macronutrient
absorption,7,12 but the associated effects on ﬂuid and electrolyte
absorption are not clear. Hyperalimentation may be accompanied
by increased faecal ﬂuid and electrolyte losses, which could
aggravate abdominal discomfort and accentuate needs for
parenteral ﬂuids, electrolytes or oral rehydration solutions.
Anti-diarrhoeals13,14 reduce intestinal motility, whereas anti-
secretory agents15–17 reduce upper GI secretions, but their effect
on macronutrient absorption remains to be established.18
Stimulation of remnant bowel adaptation with growth
hormone19 or glucagon-like peptide 2 (GLP-2)20 has improved
energy and wet weight absorption in patients with intestinal
insufﬁciency or failure that were already well adapted,21 probably
mediated by local release of growth factors such as insulin-like
growth factor 1.22
In this context, colostrum, the ﬁrst milk produced after birth in
mammals, has interesting properties in addition to its normal
role to stimulate growth and maturation of the newborn gut.23
In growing SBS piglets, colostrum has been shown to improve
intestinal adaptation.24,25 Colostrum is rich in immunoglobulins,
antimicrobial peptides (lactoferrin and lactoperoxidase) and a
number of other bioactive molecules and growth factors.26 The
protein content is very high (B11% v/v), and the whey proteins
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include a-lactalbumin, b-lactoglobulin, serum albumin, immuno-
globulins, lactoferrin and peptide hormones such as growth
hormone27 and insulin-like growth factors,28 epidermal growth
factor,29 betacellulin,27 transforming growth factor b30 and
platelet-derived growth factor.26 In cell-lines, animal models31,32
and human studies,33 such growth factors have shown potential
for proliferation and differentiation of both immature and mature
cells in the gastrointestinal tract.
On this background, we hypothesised that a supplement of
bovine colostrum would enhance intestinal adaptation and function
in adult SBS patients compared with a standard milk-based protein
control. To test our hypothesis, we evaluated effects of 4 weeks
supplement of colostrum or an iso-protein-energy control to SBS
patients on nutrient and ﬂuid balances, body composition and
functional indices (lung function and handgrip strength tests).
PATIENTS AND METHODS
Patients
Twelve SBS patients (ﬁve females, seven males; 55.7±10.7 years) were
recruited based on a faecal energy excretion above 1.5MJ as previously
measured (Table 1). Nine patients suffered from intestinal failure, ﬁve received
parental nutrition, and four received ﬂuids and electrolytes exclusively. Three
patients had intestinal insufﬁciency and did not need parenteral support. Ten
patients suffered from SBS due to Crohn’s disease. None of these patients had
active inﬂammatory bowel disease (IBD). The Ethics Committee for Medical
Research in Copenhagen, Denmark approved the protocol (H-D-2008-112).
Procedures were followed in accordance with the ethical standards of the
Helsinki Declaration of 1975, as revised in 1983. All patients signed informed
consent before participation in the study.
Diets and study protocol
Colostrum was obtained from a dairy farm from cows (breed: Danish Red)
at the ﬁrst milking post partum (Assendrup Hovedgaard, Haslev, Denmark)
with a measured energy of 534 kJ/100ml (protein: 10.6 g/100ml,
carbohydrate 3.6 g/100ml, fat 5.5 g/100ml, sodium 21mmol/l). Colostrum
was tested for sufﬁcient concentrations of immunoglobulins (Colostru-
meter 290855, Kruuse, Odense, Denmark) ensuring levels of immunoglo-
bulin above 50mg/ml, as a positive correlation exists between protein
concentration and growth factors (insulin-like growth factor-1 and 2, and
transforming growth factor-b) in colostrum.28 Colostrum was frozen at
 20 1C and sterilised (gamma irradiation 10 kGy, Sterigenics, Hørsholm,
Denmark). The colostrum used was not standardised and inevitable
variations between batches were not investigated further.
A nutrient-matched control was produced using semi-skimmed milk,
cream and a commercial whey protein powder (Lacprodan DI 9224, ARLA
Foods Ingredients, Aarhus, Denmark) with a measured energy content of
455 kJ/100ml (protein: 10.5 g/100ml, carbohydrate 4.8 g/100ml, fat
3.2 g/100ml, sodium 34mmol/l). Patients kept track of intake using a
diary designed for the study. They were randomised and given 1 week
supplements by laboratory staff at a time and returned empty containers
to verify compliance. Whey/casein ratio in colostrum is 75/25%, and this
was similar in the control diet. A slightly higher content of carbohydrate
and lower concentration of fat was present in the control diet, relative to
the colostrum diet.
In this randomised, double-blind, controlled, cross-over study patients
received 4 weeks oral supplement consisting of 250ml colostrum or 250ml
control twice daily (morning and evening) in addition to their habitual diet.
Patients defrosted colostrum and control on a daily basis. Test periods
were separated by a washout period of at least 4 weeks, where patients
only received their habitual diet. During baseline periods patients were
given 500ml of water instead of colostrum or control.
Patients were admitted four times to the hospital for 72-h nutrient, ﬂuid
and electrolyte balance studies (Figure 1). During ﬁrst day, oral intake,
nutrients and beverages were weighed and registered, and double portions
were made and collected to determine the content of energy (bomb
calorimetry), carbohydrate (Englyst’s method), nitrogen (Kjeldahl’s method)
and fat (titration analyses).16 Content of sodium and potassium (ﬂame
photometry), and calcium and magnesium (atomic absorption spectro-
photometry) were also determined as previously described.16 The patients
received the same ﬁxed diet composed at day 1 throughout their 72h
admissions. Urine and faecal output were collected and frozen at  20 1C.
The absolute intestinal absorption was calculated as the difference between
oral intake and faecal output, and relative absorption was calculated as
the absolute absorption divided by oral intake. All patients’ medication
and parental support were kept constant during the study period.
At day 1 of each admission, a general physical examination was
performed, providing a medical record and measurement of handgrip
strength (Jamar 5030JI Hydraulic Hand Dynanometer, Sammons Preston
Rolyan, Bolingbrook, IL, USA) according to previously validated methods.34
At day 2, a test was performed to record meal-stimulated, endogenous
GLP-2 secretion. Fasting from midnight, baseline blood samples were
taken at the time  15min at 0830 hours. Patients’ individual breakfast
was then served including treatment (water, colostrum or control), and
blood samples were collected at 10, 20, 30, 45, 60, 90, 120 and 180min
after the meal to measure plasma GLP-2.35 At day 3, basal metabolic rate
was measured under standardised conditions by indirect calorimetry
(Jaeger, Oxycon pro, Hoechberg, The Netherlands). Static and forced
spirometry was performed; lung diffusion capacity for carbon monoxide
(DLCO) was evaluated by single breath test (SB); and respiratory muscle
strength was measured according to standards of the European
Respiratory Society.36–38 Body composition was ﬁnally measured using
dual-energy X-ray absorptiometry (DEXA scanning; Norland XR-800,
Cooper Surgical Company, Trumbull, CT, USA), and blood chemistry
values (packed cell volume, haemoglobin, leukocytes, platelets, creatinine,
glucose, potassium, magnesium, sodium, C-reactive protein, alanine-
transaminase, amylase, alkaline phosphatase, D-vitamin, parathyroid
hormone) were measured at the hospital laboratory according to the
European standards.
Statistics
All paired data have been tested for normal distribution, and results
are presented as means±standard deviations (s.d.). Two-sided Student’s
t-tests evaluated effects of the colostrum and control diets, compared
Table 1. Clinical characteristics of participants
Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 Pt 6 Pt 7 Pt 8 Pt 9 Pt 10 Pt 11 Pt 12
Sex M M F F M M M M F M F F
Age (years) 44 33 54 66 48 57 65 72 57 50 62 60
Height (m) 1.84 1.63 1.63 1.68 1.70 1.73 1.73 1.72 1.74 1.83 1.66 1.70
Weight (kg) 65.8 48 56.5 69.9 62.3 67.3 56.2 72 63.5 66.8 57 37
BMI (kg/m2) 19.4 18.1 21.3 24.8 21.6 22.5 18.8 24.3 21.0 19.9 20.7 12.8
Primary diagnosis mb.
Crohn
mb.
Crohn
mb.
Crohn
mb.
Crohn
mb.
Crohn
mb.
Crohn
mb.
Crohn
mb.
Crohn
mb.
Crohn
mb.
Crohn
Ileus Ileus
Remnant small bowel (cm) 100 80 150 30 250 280 340 250 200 150 50 350
Percentage of colon in
continuity
50 66 0 0 0 0 0 45 0 50 50 0
Nutritional status PF PN PF PN PF OA OA OA PF PN PN PN
Patient data included in
analysis
þ þ þ þ   þ þ þ þ  
Abbreviations: mb., morbus; OA, oral autonomy; PN, parental nutrition; PF, parental fluids.
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with baseline measurements, and effects between colostrum and the
control. P-values lower than 0.05 were considered signiﬁcant.
RESULTS
Complete data sets were obtained for eight patients. Two patients
discontinued due to nausea and vomiting during supplementa-
tion with colostrum (patients 11 and 12). One patient left the
study due to personal problems, not otherwise related to the
study (patient 8). The investigators excluded one patient’s data
(patient 7), as major dental work impaired his ability to comply
with the ﬁxed meals during balance studies (Table 1).
Energy and nutrient balance studies
As shown in Table 2, total energy intake was signiﬁcantly higher
during oral supplements (colostrum: 2.37±0.77, control:
2.50±0.48MJ/d, both Po0.0001) compared with baseline condi-
tions, where water was supplied. Absolute energy absorption was
signiﬁcantly increased during both treatments (colostrum:
1.46±1.02, P¼ 0.005; control: 1.76±1.46MJ/d, P¼ 0.01), com-
pared with baseline conditions. No difference in absolute
or relative energy absorption was seen between colostrum and
control treatments. The increase in total energy intake derived
mainly from increased protein intake (Table 2) and was similar
during both treatments (1.49±0.23MJ/d and 1.38±0.20 kJ/d for
colostrum and control, respectively, both Po0.0001 relative to
Figure 1. Model of study design.
Table 2. Results from energy, protein, carbohydrate and fat balance studies
Mean (±s.d.)
n¼ 8
Baseline 1 Treatment 1 P-value Baseline 2 Treatment 2 P-value Control vs
colostrum
Treatment Water Colostrum Water Control P-value
Energy balance
Diet (MJ/d) 13.56 (4.42) 15.93 (4.55) o0.0001 13.71 (4.45) 16.20 (4.34) o0.0001 0.31
Faeces (MJ/d) 6.00 (3.40) 6.91 (3.61) 0.03 5.44 (3.22) 6.17 (3.86) 0.11 0.14
Absolute absorption (MJ/d) 7.56 (3.09) 9.02 (3.35) 0.005 8.27 (3.35) 10.03 (4.01) 0.01 0.15
Relative absorption (%) 56 (21) 57 (19) 0.61 60 (22) 62 (25) 0.49 0.24
Protein balance
Diet (MJ/d) 2.18 (0.65) 3.67 (0.70) o0.0001 2.29 (0.81) 3.67 (0.82) o0.0001 0.98
Faeces (MJ/d) 1.12 (0.55) 1.66 (0.69) 0.001 1.00 (0.46) 1.45 (0.80) 0.02 0.06
Absolute absorption (MJ/d) 1.05 (0.54) 2.01 (0.75) 0.0004 1.29 (0.72) 2.31 (0.88) 0.0003 0.14
Relative absorption (%) 48 (25) 55 (19) 0.10 64 (25) 63 (23) 0.07 0.11
Carbohydrate balance
Diet (MJ/d) 5.02 (1.54) 5.46 (1.52) 0.001 5.02 (1.58) 5.61 (1.46) o0.0001 0.04
Faeces (MJ/d) 0.90 (0.52) 0.95 (0.52) 0.06 0.81 (0.48) 0.95 (0.61) 0.07 0.99
Absolute absorption (MJ/d) 4.12 (1.56) 4.51 (1.52) 0.005 4.21 (1.66) 4.66 (1.63) 0.004 0.16
Relative absorption (%) 82 (17) 83 (14) 0.38 84 (18) 83 (16) 0.408 0.83
Fat balance
Diet (MJ/d) 5.51 (2.02) 6.32 (2.24) 0.04 5.64 (1.88) 6.21 (1.95) 0.01 0.71
Faeces (MJ/d) 2.97 (1.88) 3.30 (1.95) 0.25 2.74 (1.82) 2.93 (1.84) 0.30 0.18
Absolute absorption (MJ/d) 2.54 (1.31) 3.02 (2.35) 0.36 2.91 (1.48) 3.28 (1.98) 0.17 0.61
Relative absorption (%) 46 (24) 48 (26) 0.80 52 (25) 53 (33) 0.66 0.53
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baseline). Faecal protein losses were similarly increased during
treatments (0.53±30 and 0.44±40MJ/d, respectively), leading to
a similar net increase in total protein absorption in the two groups
(0.96±0.42 and 1.03±0.44MJ/d).
Total carbohydrate intake was signiﬁcantly higher during
treatments with signiﬁcantly higher values for control compared
with colostrum (0.44±0.24 and 0.59±0.21MJ/d colostrum/
control; Po0.05; Table 2). However, no difference in faecal
carbohydrate excretion, and no differences in absolute or relative
carbohydrate absorption were seen between the two treatments.
As for protein and carbohydrate, fat intake was signiﬁcantly higher
during treatment periods (colostrum: 0.81±0.94 and control:
0.57±0.49MJ/d), whereas faecal fat excretion remained the same,
with no difference in absolute or relative fat absorption between
the groups (Table 2).
Wet weight and electrolytes balances
In spite of keeping oral wet weight intake constant during all four
admissions (Table 3), faecal wet weight excretion signiﬁcantly
increased during both oral supplementations (colostrum:
231±248 g/d, P¼ 0.04; control: 319±299 g/d, P¼ 0.02) compared
with baseline conditions. No difference in faecal wet weight
excretion was seen between oral colostrum and control treatment.
Relative wet weight absorption signiﬁcantly decreased during
control supplementation (8.6±9.3%, P¼ 0.04) compared with
baseline, whereas the decrease in relation to colostrum supple-
mentation did not reach statistical signiﬁcance (6.3±10.1%,
P¼ 0.12). No difference in relative wet weight absorption between
colostrum and control treatment was seen (P¼ 0.35). The increase
in faecal wet weight excretion was accompanied by a signiﬁcant
decrease in urine output in patients receiving placebo
(444±309 g/d, P¼ 0.005) compared with baseline, and a marginal
decrease during colostrum treatment (175±289 g/d, P¼ 0.13).
There was no difference in urine output between colostrum and
control treatment (P¼ 0.59).
Absolute sodium absorption increased signiﬁcantly during
colostrum treatment compared with baseline conditions
(21.4±21.0mmol/d, P¼ 0.02), but no difference in absolute
sodium absorption was seen between colostrum and control
treatment (Table 3). Likewise, relative sodium absorption did not
differ between the two treatments.
All data from nutrient, ﬂuid and electrolyte balance studies have
also been analysed, with a distinction between patients with parts
of colon or without parts of colon. No distinctions were found for
any results, whether patients had remnants of colon or not.
Body composition, basal metabolic rate, handgrip strength
and lung function
Total body weight increased signiﬁcantly (0.9±0.3 kg, P¼ 0.01)
compared with baseline conditions for the control treatment
(Table 4). This was accompanied by an increase in lean body mass
(1.1±1.3 kg, P¼ 0.0495) without any effects on fat mass
( 0.03±1.59 kg, P¼ 0.95). For treatment with colostrum, no
changes were observed in body weight (0.0±1.6 kg, P¼ 0.98),
lean body mass ( 0.35±1.9 kg, P¼ 0.63) or fat mass
(0.37±1.06 kg, P¼ 0.35), relative to values at baseline. No
differences were seen comparing colostrum and control.
There were no signiﬁcant changes in basal metabolic rate
during any of the two treatments (colostrum: 87.56±10.79 kJ/kg/d,
control: 87.32±7.12kJ/kg/d), compared with baselines (baseline 1:
86.99±11.40kJ/kg/d and baseline 2: 87.54±10.72 kJ/kg/d), and no
changes between the colostrum treatment and control treatment.
Handgrip strength increased during both the treatments
(Table 4) on the dominant hand side (right hand side for all
participants), relative to baseline values (colostrum 3.1±3.3 kg,
control diet 2.6±2.8 kg, both Po0.05), and no differences were
observed between the two treatments.
Assessment of respiratory muscle strength (maximum inspira-
tory pressure and maximum expiratory pressure) showed normal
values (Table 4). No changes were seen during either colostrum
or control treatment compared with baseline measurements, or
between the two treatments.
Blood chemistry and meal-stimulated GLP-2 levels
The blood chemistry values showed no signiﬁcant changes during
the two treatments compared with baseline values, and no
signiﬁcant changes between the two treatments were observed.
During supplementation with colostrum, bilirubin (2±3 mmol/l,
Po0.05) and phosphate (0.15±0.15mmol/l, Po0.05) concentra-
tions increased, compared with baseline measurements, but no
signiﬁcant differences were seen between colostrum and control
treatments. Conversely, the control diet increased plasma albumin
(3±3 g/l, Po0.05) and blood CO2 (2±2mmol/l, Po0.05), and
decreased ionised calcium ( 0.04±0.03mmol/l, Po0.05), but for
none of these parameters were there any signiﬁcant differences
between the two treatments. Both diets increased blood urea
(colostrum: 1.4±1.7mmol/l, control: 1.9±1.6mmol/l, both
Po0.05) and urinary urea (colostrum: 81±72mmol/d, control:
72±89mmol/d, both Po0.05), with no differences seen between
the two treatments.
Table 3. Results from wet weight and sodium balance studies
Mean (±SD)
n¼ 8
Baseline 1 Treatment 1 P-value Baseline 2 Treatment 2 P-value Control vs
colostrum
Treatment Water Colostrum Water Control P-value
Wet weight balance
Diet (g/d) 3964 (1580) 4053 (1549) 0.32 4052 (1571) 4059 (1562) 0.57 0.63
Faeces (g/d) 2108 (1279) 2339 (1392) 0.03 1900 (1226) 2220 (1302) 0.02 0.39
Absolute absorption (g/d) 1855 (1178) 1714 (1349) 0.23 2152 (1268) 1839 (1271) 0.03 0.36
Relative absorption (%) 47 (38) 42 (47) 0.12 53 (39) 45 (44) 0.04 0.35
Parenteral nutrition (g/d) 996 (1384) 996 (1384) 1.00 1004 (1405) 994 (1378) 0.35 0.35
Urine (g/d) 1532 (547) 1357 (469) 0.13 1727 (617) 1283 (421) 0.005 0.59
Sodium balance
Diet (mmol/d) 225 (129) 247 (130) 0.002 231 (122) 249 (131) 0.003 0.38
Faeces (mmol/d) 185 (148) 186 (153) 0.98 168 (144) 190 (153) 0.09 0.78
Absolute absorption (mmol/d) 40 (111) 61 (121) 0.02 63 (118) 60 (126) 0.79 0.93
Relative absorption (%) 17.6 (74) 24.7 (67) 0.07 27.3 (75) 23.9 (68) 0.74 0.71
Parenteral nutrition (mmol/d) 80 (106) 80 (106) 1.00 80 (106) 80 (106) 1.00 1.00
Urine (mmol/d) 104 (79) 106 (93) 0.92 108 (73) 94 (64) 0.26 0.55
Colostrum and short bowel syndrome
P Lund et al
1062
European Journal of Clinical Nutrition (2012) 1059 – 1065 & 2012 Macmillan Publishers Limited
Colostrum and control supplements added to the patients’ own
breakfast did not increase the circulating plasma GLP-2 compared
with baseline values, and there were no differences at the various
time points measured between the two treatments. No signiﬁcant
differences were found for the area under the curves for the four
meal tests (baseline 1: 2395±459, colostrum: 2877±470, baseline
2: 2266±259, control: 3083±744).
DISCUSSION
In SBS patients, treatments aim to maximise intestinal absorption,
thereby minimising diarrhoea and maintaining adequate nutrition
and hydration. We hypothesised that supplementation with
protein-rich milk supplements would enhance intestinal adapta-
tion and function in adult SBS patients, and that bovine colostrum
would be superior to a milk-based energy- and protein-matched
control. In fact, treatment with both supplements was associated
with improved nutrient absorption and improvements in func-
tional and biochemical markers relative to baseline values, but
there was no difference between the two treatments. Hence, we
could not document an effect of the high concentrations of
bioactive factors speciﬁcally found in colostrum.
It is possible that gastric pH is higher in newborns than in
adults, including SBS patients, although ﬁve out of the eight
patients received proton-pump inhibitors in this study. This may
affect the degree of milk protein degradation in adult SBS patients
compared with infants, and the bioactivity in the colostrum may
have been eliminated before exerting its effects in the small
intestine. Most studies documenting effects of colostrum in vivo
have been performed in infants39 and possibly, proteolytic
degradation of colostral bioactives is lower than in adults.
Furthermore, the sensitivity of the gut cells and receptors
toward stimulation from colostrum may be higher in an
immature and developing gut, relative to the gut in adult SBS
patients especially ones that are already well adapted. Limited
information is available about degradation and absorption of milk
proteins in SBS patients,40 and besides differences in pH, also
gastric emptying and transit time may inﬂuence effects of speciﬁc
bioactive factors. In general, SBS is characterised by rapid gastric
emptying41 and short intestinal transit time.42 Together these
factors may have resulted in a low exposure of the intestinal
epithelial lining to the bioactive factors in colostrum, and thus
preventing their effects on intestinal adaptation beyond the
effects induced by the additional nutrient input.
The group of SBS patients included in the study was very
heterogeneous regarding demographics and remnant bowel
function. In a small sample size, this might result in a lower ability
to detect possible effects of colostrum. An effect-heterogeneity
may also exist in different subgroups within the spectrum of SBS
patients. In addition, all the SBS patients included in this study
were well adapted to their short bowel situation. Taken together,
this could restrict the ‘room for improvement’ in relation to
colostrum treatment. However, in a similar setting, it has been
possible to demonstrate signiﬁcant improvements in intestinal
function employing other treatment modalities, and therefore, the
effects of colostrum seem to be so modest that the clinical
relevance is negligible.20,21,43 In fact, two of the eight patients
showed a negative value for relative improvement of intestinal
absorption; the other six had improvements, though mainly minor,
in the magnitude of 2–3%, and one patient improved his relative
absorption with 11% from 47 to 58%.
Sodium absorption was shown to be relatively low in these
patients. The large standard deviation (106mmol/d) depicts the
large heterogeneity of the SBS group including both patients with
intestinal insufﬁciency and patients with intestinal failure.
The increase in sodium absorption in relation to colostrums
treatment, compared with baseline measurements, is likely to be
due to the increase in the overall sodium intake. Although the
sodium content was equivalent in the control treatment, this
excess sodium intake did not lead to increases in sodium
absorption compared with baseline measurements in the
matched control. It is not known if this ﬁnding was coincidental,
but as no signiﬁcance was found between the two treatments, the
clinical signiﬁcance is questionable.
By choosing to compare the effects of oral supplements to the
effects of water, the study also evaluated effects of short-term oral
hyperphagia in SBS patients. Both supplements signiﬁcantly
improved the absolute absorption of energy, protein and
carbohydrate compared with water at baseline measurements.
These apparent beneﬁts of oral hyperphagia were, however,
accompanied by increased wet weight excretion and a decreased
urine production. This could deteriorate the ﬂuid balance of the
SBS patients or increase the need for parenteral ﬂuids and thereby
jeopardise overall treatment aims.
Habitual oral intake between admissions was not controlled in
our study. Thus, we cannot evaluate if an increase in energy
absorption was compensated by a reduction in the patients’
habitual diets or lead to an increase in their physical activity.
However, in patients receiving control supplement, there was a
Table 4. Results from body composition and functional indices
Mean (±s.d.)
n¼ 8
Baseline 1 Treatment 1 P-value Baseline 2 Treatment 2 P-value Control vs
Colostrum
Treatment Water Colostrum Water Control P-value
Body composition
Spine BMD (g/cm2) 0.904 (0.17) 0.909 (0.17) 0.66 0.903 (0.18) 0.912 (0.17) 0.45 0.67
Spine T-score (g/d)  1.66 (1.26)  1.61 (1.21) 0.53  1.67 (1.26) 1.58 (1.21) 0.43 0.69
Spine Z-score (g/d)  0.87 (1.5)  0.82 (1.43) 0.51 0.87 (1.5) 0.79 (1.44) 0.42 0.70
Total BMC (g) 2.46 (0.46) 2.46 (0.47) 0.92 2.43 (0.47) 2.50 (0.50) 0.27 0.50
Total lean mass (kg) 44.34 (8.8) 43.99 (7.6) 0.63 43.48 (8.1) 44.59 (8.0) 0.049 0.40
Total fat mass (kg) 16.45 (9.9) 16.83 (9.6) 0.35 16.84 (8.9) 16.81 (9.3) 0.96 0.97
Total weight (kg) 63.3 (9.4) 63.3 (9.4) 0.98 62.7 (9.5) 63.6 (9.8) 0.01 0.53
Handgrip strength test
Right hand side (kg) 35.6 (8.4) 38.8 (10) 0.03 35.6 (7.7) 38.2 (8.4) 0.03 0.50
Left hand side (kg) 36.6 (11.1) 36.9 (9.5) 0.71 35.8 (10) 35.9 (9.8) 0.92 0.31
Handgrip strength mean (kg) 36.1 (8.6) 37.9 (9) 0.04 35.7 (8.2) 37.1 (8.3) 0.12 0.38
Lung function test
MIP (cm H2O) 103.75 (24.9) 103.38 (20.3) 0.88 101.87 (22.4) 97.75 (22.8) 0.22 0.05
MEP (cm H2O) 115.37 (21.5) 118.25 (18.9) 0.66 114.75 (22.8) 113.37 (28.3) 0.75 0.55
Abbreviations: BMC, bone mineral content; BMD, bone mineral density; MEP, maximum inspiratory pressure; MIP, maximum inspiratory pressure.
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signiﬁcant increase in body weight. This could be related to a
better tolerance and compliance of this supplement, compared
with colostrum, or to differences in the effects on appetite,
where colostrum supplement could reduce regular oral intake
of the habitual diet more than the control supplement. Although
colostrum has been found to increase endogenous GLP-2
responses44 in animal studies, this was not the case in our
study. A previously described reduced meal-stimulated endo-
genous GLP-2 secretion in these patients45 was also found in
our study probably due to resection of the GLP-2 producing parts
of the intestine in these patients.
Studies that measure effects of protein supplementation on
body composition and muscle strength are often performed in
combination with exercise.46 In this study, protein supplements
were added without controlling for exercise levels, and our SBS
patients were not particularly malnourished when entering the
study. This may explain why the functional effects of increased
protein intake were relatively modest in our study. However,
we did ﬁnd a signiﬁcant effect of 4 weeks high-protein
supplementation on handgrip strength, a validated test to
evaluate nutritional status and functional outcome in patients.47
On the other hand, we failed to ﬁnd any effects on lung function,
another test to evaluate nutritional status and functional outcome
in patients.48 No improvements were detected in respiratory
muscle strength (maximum inspiratory pressure and maximum
expiratory pressure), but again, our patient group was not
particularly malnourished, and no attempts were made to
control for exercise levels, which possibly could affect markers
of functional outcome.
The protein intake was high, and despite severe protein
malabsorption, the absolute absorption of protein for some of
the patients exceeded the limits of standard dietary recommen-
dation of 1 g/kg body weight/day during supplementation
periods. Concern regarding high protein loads has been related
to possible detrimental renal effects.49 In this study, no patients
with renal impairment were included, and no changes in plasma
creatinine were seen during the study. The excessive protein
intake and absorption were reﬂected in the increased urea losses
in the urine.
In conclusion, our study supports the beneﬁts of oral protein-
energy supplements to increase protein-energy absorption in SBS
patients. Even though SBS patients suffer from compromised gut
function and malabsorption, and even though the patients were
well adapted, had Crohns disease and thus may have a reduced
adaptive capacity, it is possible to maximise absolute nutrient
absorption by increasing oral intake, that is, hyperphagia. Using
protein supplements in high doses did not have any negative
health impacts. In fact, our SBS patients improved their muscle
strength and lean body mass, even in the absence of enhanced
physical exercise. However, the increased diarrhoea and reduced
urine production in relation to the protein-energy supplementa-
tion may limit the use, as maintenance of ﬂuid balance is equally
crucial for SBS patients. In spite of the content of putative
beneﬁcial components, colostrum was not superior to an energy-
and protein-matched control in its effects on intestinal absorption,
body composition or functional tests.
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